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Background: The risk of surgical site infection (SSI) for breast surgery in patients
without additional risk factors is low, below 5%. Evidence shows the risk of SSI
is significantly elevated in patients undergoing immediate breast reconstruction
(IBR). However, there is no consensus regarding the use of extended antibiotic
prophylaxis. We aim to determine the effect of extended antibiotic prophylaxis on
the incidence of SSI after IBR.
Methods: PubMed and Scopus were searched by 2 independent reviewers. Data
abstracted included types of study, basic characteristics, detailed antibiotic prophylaxis
information, SSI event, and other secondary outcomes. We calculated the risk ratio
(RR) and 95% confidence interval (CI) for each study and used a random-effects
model to estimate the results. Study quality, bias, and heterogeneity were also analyzed.
Results: A total of 11 studies (15,966 mastectomy procedures) were included. We
found an overall 5.99% SSI rate in our population. Three studies comparing topical antibiotics with no topical antibiotics demonstrated statistical significance (RR
= 0.26, 95% CI: 0.12–0.60, P = 0.001), whereas 8 studies comparing extended systemic antibiotics with standard of care found no statistical significance (RR = 0.80,
95% CI: 0.60–1.08, P = 0.13).
Conclusions: In the setting of IBR following mastectomy, there is insufficient evidence for the use of extended prophylactic antibiotics to reduce SSI rates. Welldesigned randomized controlled trials in patients undergoing IBR should be
conducted to determine the appropriate regimen and/or duration of prophylactic antibiotics on SSI outcomes. (Plast Reconstr Surg Glob Open 2020;8:e2613;
doi: 10.1097/GOX.0000000000002613; Published online 27 January 2020.)

INTRODUCTION

Breast cancer is one of the most common malignancies diagnosed in women and comprises about 18% of all
female cancers.1 Surgery is the primary modality for the
treatment of breast cancer, depending on tumor stage.2
An increasing number of breast cancer patients are opting
for mastectomy with reconstruction for treatment.
Postmastectomy reconstruction can surgically restore
the shape of the breast and provide breast cancer patients
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with psychological benefits.3,4 There are 2 types of postmastectomy reconstructions: autologous tissue flap and tissue
expander/implant. Although autologous tissue provides
the most lasting and natural outcomes, implant-based
breast reconstruction is the more popular procedure,
accounting for about 80% of postmastectomy reconstructions.5,6 Breast reconstruction can be divided by timing into
immediate breast reconstruction (IBR) and delayed breast
reconstruction (DBR). IBR, compared to DBR, offers a
native inframammary fold and a pliable skin envelope for
a more natural appearance.7 IBR also reduces psychological impact on patients8 and thus may be favored by some
patients. However, compared to DBR, IBR is associated
with greater risk of surgical site infection (SSI).9,10
SSI is defined as infection of the superficial incision,
organ, and/or space after surgery. Accordingly, there are
3 categories of SSI: superficial incisional SSI, deep incisional SSI, and organ/space SSI.11 The rate of SSI is strongly
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associated with the type of surgical wound. The Centers for
Disease Control (CDC) published a guideline in 1985,12
which classified surgical wounds into clean, clean/contaminated, contaminated, and dirty, with the SSI rate of
1%–5%, 3%–11%, 10%–17%, and over 27%, respectively.13
The occurrence of SSI can impact the postoperative recovery process and result in extra cost and rate of hospital
readmissions.
Breast surgeries are classically categorized as clean,14
and according to the CDC and the Surgical Care
Improvement Project, for breast surgical procedures,
antibiotics should be discontinued within 24 hours after
surgery.12 However, among breast surgeries, IBR with a
tissue expander/implant is associated with higher SSI,
with the average SSI rate ranging from 5% to as high as
35%.10,15,16
In the setting of IBR, several studies supported the use
of extended prophylactic antibiotics to prevent SSI,17–19
but others stated that extended antibiotic usage could
lead to systemic side effects and the development of
resistant organisms.20–22 Thus, there is still no consensus
regarding the extended usage, regimens, and timing of
prophylactic antibiotics for mastectomy with IBR. This
meta-analysis aims to determine the efficacy and safety
of extended prophylactic antibiotics on SSI after mastectomy with IBR.

PATIENTS AND METHODS
Search Strategy

Our study followed guidelines published by the Centre
for Reviews and Dissemination (CRD) and the Cochrane
Collaboration and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses criteria .23,24 A
protocol for this systematic review was registered using
Prospero (CRD42019127536).
We included patients undergoing mastectomy with
IBR, or mixed types (IBR and DBR) if the study had separate outcomes for IBR and DBR groups. Both randomized
controlled trials (RCTs) and observational studies were
included. Studies that compare pre-, peri-, postoperative
extended prophylactic antibiotics with standard of care
were included. Studies with no comparison group were
excluded.
Two reviewers independently assessed the title and
abstract of articles identified by the search described
earlier. Two reviewers applied the inclusion and exclusion criteria, and disagreements were resolved by reading the full text. A third reviewer examined the article
and made the final decision if still undecided. The
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses flowchart diagram of literature retrieval is
shown in Fig. 1.
Data Extraction

Two reviewers independently extracted the data. Data
were collected from each study: the first author, publication year, study design, number of procedures, type
of IBR, antibiotics (ie, regimen name, dose, duration of
treatment), and outcomes.
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Quality Assessment for Included Studies

Two reviewers independently assessed the study quality using the Newcastle–Ottawa Scale.25 The Newcastle–
Ottawa Scale is used to evaluate non-RCTs, with 1 version
for case–control studies and the other for cohort studies.
Both versions of the scale consist of 8 multiple-choice questions that address subject selection and comparability (of
cases and controls in case–control studies and of cohorts
in cohort studies) and the assessment of the outcome (in
case–control studies) or exposure (in cohort studies).
Dealing with Missing Data

For those articles which met inclusion criteria but had
incomplete data (ie, missing type of standard of care of comparison group, or no details of antibiotic use of extended
antibiotics group), we emailed the corresponding author of
that article. If corresponding authors did not respond after
3 weeks, the article was labeled as having incomplete data,
and this would be mentioned in the results section.
Outcome Measures and Data Synthesis

All statistical analyses were performed by Review
Manager V.5.3 (The Cochrane Collaboration, Software
Update, Oxford, UK). We calculated the risk ratio (RR) at
95% confidence interval (CI) for each study, weighted by
the number of events in each study. Statistical significance
was defined as 2-tailed alpha < 0.05. Forest plots were generated for graphical presentations for clinical outcomes,
and we used I2 statistics to define the heterogeneity of
each study. Mantel-Haenszel method was used to conduct
meta-analysis, and because I2 was >50%, we used the random-effects model instead of the fixed-effects model. We
did subgroup analyses where the data were applicable.
Assessment of Heterogeneity

We assessed the heterogeneity between study results
using the I2 statistics. The result is a percentage of total
variation among studies due to heterogeneity. I2 is commonly divided into 3 categories—low, moderate, and high,
with upper limits of 25%, 50%, and 75%, respectively.26
Sensitivity Analysis

We assessed the influence of a single study on the overall
effect by sequentially removing 1 study at a time to test the
robustness of the pooled results to further verify whether
any study had an excessive influence on the overall results.

RESULTS
Results of the Search

A total of 597 articles were identified, of which 297
articles were excluded as they were ineligible publication
types. After initial screening of the remaining 300 original articles, we further excluded 289 articles because they
were irrelevant to our study topic or had incomplete data.
The details of the search strategy are shown in Fig. 1.
Characteristics of Included Studies

A total of 11 studies (15,966 mastectomy procedures)
were included, 10,688 in the extended antibiotics arm and
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Fig. 1. The PRISMA diagram of literature retrieved. PRISMA, Preferred Reporting Items for Systematic Reviews and
Meta-Analyses.

5,278 in the comparison arm. One was an RCT,21 and 10
studies17–20,22,27–31 were retrospective studies with 1 matched
cohort study.31 The studies were published between 2009
and 2018, with sample sizes ranging from 112 to 7,443
mastectomies. The main characteristics of all 11 studies
are presented in Table 1.
Type of Procedures

All procedures were unilateral or bilateral mastectomy
with IBR. Immediate breast implant, tissue expander, and
autologous flap (including latissimus dorsi flap and subpectoral flap) placement were described in 7, 3, and 2
studies, respectively.
Timing and Types of Antibiotics

Eight studies evaluated the usage of extended postoperative systemic prophylactic antibiotics compared to standard of care, where antibiotics are discontinued within 24
hours after breast surgery.12 However, the duration and
types of antibiotics used vary between studies. In 5 of 8
studies,17,18,21,22,31 all patients were given pre- or perioperative antibiotics as baseline treatment, whereas the other 3
studies20,29,30 had incomplete data on antibiotic usage in

their comparison groups. The study design was also different. Of the 8 studies, 1 study was an RCT, 2 studies were
claims databases with a large sample size, and 5 studies
were single-site retrospective studies.
Three studies evaluated the usage of postoperative
topical antibiotics compared to no postoperative topical antibiotics. Two articles19,28 focused on the usage of
topical mupirocin ointment and irrigation with both the
extended antibiotics group and comparison arm using the
same pre-/ peri- and postoperative antibiotics. The third
article27 used a novel antibiotic bead compared to comparison, where both arms had the same preoperative and
irrigation antibiotics.
Synthesis of Results
Incidence of SSI

We found an overall average SSI rate of 5.99% in mastectomy procedures. Heterogeneity within the interventions
used in the study prevented pooling of all the studies for analysis. Analysis of 8 studies comparing extended systemic antibiotics with standard of care found no statistical significance
(RR = 0.80, 95% CI: 0.60–1.07, P = 0.13) (Fig. 2); as 1 RCT and
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Table 1. Characteristics of Included Studies (n = 11)
Type of
Reconstruction

No.
Operations

Study

Study Design

Avashia et al17
Hunsicker et al19

Retrospective IBR TE
Retrospective IBR implant

138
535

Clayton et al18

Retrospective IBR implant

250

Goh et al20

Retrospective IBR TE,
latissimus dorsi,
subpectoral
Retrospective IBR implant

240

McCullough
et al22
Murray et al28

Retrospective IBR implant

378

Retrospective IBR TE

200

Olsen et al29

Retrospective IBR implant,
flap, both
RCT
IBR implant

5,938

Retrospective IBR implant

7,443

Retrospective IBR implant

605

Kenna et al27

Phillips et al21
Ranganathan
et al30
Townley et al31

127

112

Intervention
Group
Antibiotics
Postoperative
> 24 h
Postoperative
irrigation
for 96 h
Postoperative
> 24 h
Postoperative
> 24 h

Intervention
Group SSI (%)

Control Group
Antibiotics

Control Group
SSI (%)

8/119 (6.7%)
6/316 (1.9%)

Standard of care
Standard of care +
irrigation once

6/19 (31.6%)
14/219 (6.4%)

21/116 (18.1%) Standard of care
12/145 (8.3%)

Standard of care

46/134
(34.3%)
2/95 (2.1%)

Irrigation +
1/68 (1.47%)
antibiotic beads
Postoperative
24/200 (12%)
> 24 h
Topical ointment 0/23 (0%)

Standard of care

7/59 (11.86%)

Standard of care

Postoperative
> 24 h
Postoperative
> 24 h
Postoperative
> 24 h
Postoperative
> 24 h

Standard of care

24/178
(13/5%)
10/177
(5.65%)
213/2,633
(8.09%)
12/62
(19.35%)
41/1,394
(5.45%)
11/308 (3.6%)

240/3,305
(7.26%)
11/50 (22%)
166/6,049
(5.26%)
9/297 (3.03%)

Standard of care

Standard of care
Standard of care
Standard of care

TE, tissue expander.

Fig. 2. Forest plot of studies that compared systemic antibiotics to standard of care (n = 8). SOC, standard of care. RR, risk ratio. M-H,
Mantel-Haenszel.

2 claims database studies are in the group of 8 studies, we also
conducted other sensitivity analysis to check whether these
studies may have affected the results (see further “Sensitivity
Analysis” section). For the topical antibiotics group, analysis
of the 3 studies comparing topical antibiotics with no topical
antibiotics demonstrated statistically significant effect of antibiotics on reducing the incidence of SSI (RR = 0.26, 95% CI:
0.12–0.60, P = 0.001) (Fig. 3) However, this statistical significance has to be interpreted with caution, as more research is
needed to confirm the findings. The use of topical mupirocin
ointment and the use of novel antibiotic beads may not be
generalizable to many other centers’ experiences.
Wound Complications

Wound complications included hematoma, wound
dehiscence, seroma, hematoma, and mastectomy flap necrosis. Four17,19,29,30 studies measured the incidence of wound
complications, with 9,789 mastectomies on extended prophylactic antibiotics and 4,220 mastectomies on standard
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of care. Analysis of the 4 studies comparing extended prophylactic antibiotics with standard of care found no statistically significant effect on reducing the incidence of wound
complications (RR = 0.89, 95% CI: 0.78–1.03, P = 0.12). The
result is presented in Supplemental Digital Content 1, which
displays a forest plot of wound complications subgroup analysis, http://links.lww.com/PRSGO/B293).
Hospital Readmission

Only 1 study measured the incidence of hospital readmission, with 6,049 mastectomies on extended prophylactic antibiotics and 1,349 mastectomies on standard of
care. Analysis of the study comparing extended prophylactic antibiotics with standard of care found no statistical
significance in reducing the rate of hospital readmission
(RR = 1.22, 95% CI: 0.85–1.74, P = 0.28). The result is presented in Supplemental Digital Content 2, which displays
forest plot of readmission subgroup analysis, http://links.
lww.com/PRSGO/B294).

Hai et al. • Antibiotics for Breast Reconstruction

Fig. 3. Forest plot of studies that compared topical antibiotics to standard of care (n = 3). SOC, standard of care. RR, risk ratio. M-H,
Mantel-Haenszel.

Quality Assessment for Included Studies

We created a quality assessment figure based on the
Risk of Bias Tool found in the Cochrane Handbook for
Systemic Reviews of Interventions,32 and we presented the
percentages of risk in each of the 9 domains. High-quality
responses were marked “low risk.” The result is shown in
Supplemental Digital Content 3, which displays risk of
bias, http://links.lww.com/PRSGO/B295.
Sensitivity Analysis and Publication Bias

Funnel plot analysis disclosed no asymmetry around
the axis, which means that publication bias was not
detected (Fig. 4). No significant results were identified in
the “leave one out” sensitivity test.
Further Sensitivity Analysis to Understand Heterogeneity
across Studies

As there were substantial differences in the types of
studies within the 8 studies that investigated extended
antibiotics on SSI, we conducted 2 further analyses.
First, we noted that 2 studies using claims database had
88.5% of the weight (Fig. 2). We analyzed extended systemic antibiotics with and without the 2 claims database
studies, resulting in 8 and 6 studies (Fig. 2) [see figure,
Supplemental Digital Content 5, which displays a forest
plot of extended systemic prophylactic antibiotics (without 2 claims databases), http://links.lww.com/PRSGO/
B297]. In Fig. 2, RR was 0.80 (95% CI: 0.60–1.07, I2 = 61%).
In Supplemental Digital Content 5, which displays a forest
plot of extended systemic prophylactic antibiotics (without 2 claims databases) [http://links.lww.com/PRSGO/

Fig. 4. Funnel plot of included studies (n = 11). SE, standard error.
RR, risk ratio.

B297], RR was 0.93 (CI: 0.49–1.80, I2 = 79%). Both analyses
showed no overall significance, but statistical heterogeneity increased slightly. We conclude that claims databases,
even with their larger sample sizes, did not greatly alter
the RR in this instance. We also note that a random-effects
model is more accurate than a fixed-effects model due to
the heterogeneity of the studies included.
There was 1 RCT among our included studies, and we
were interested in its effect (or lack thereof) on the metaanalysis. Taken alone, the RCT reported no differences
between 24-hour antibiotics or extended antibiotics (until
drain removed), with an RR of 1.18 (95% CI: 0.47–2.95).
We conducted an analysis of extended systemic antibiotics with and without this RCT, resulting in 8 and 7 studies [Fig. 2; also see figure, Supplemental Digital Content
4, which displays a forest plot of extended systemic prophylactic antibiotics (without RCT study), http://links.
lww.com/PRSGO/B296]. In Fig. 2, RR was 0.80 (95% CI:
0.60–1.07, I2 = 61%). The weight of the RCT was 0.7%.
In Supplemental Digital Content 4, which displays a forest
plot of extended systemic prophylactic antibiotics (without RCT study) [http://links.lww.com/PRSGO/B296],
RR was 0.77 (95% CI: 0.56–1.06, I2 = 65%). Overall, the
RCT did not change the results of the 8 studies. We note
that given the nature of the study, theoretically the RCT
should have been given more weight, but our predefined
statistical method did not provide allowances for ad hoc
increases in statistical weight.

DISCUSSION

For patients who are opting for mastectomy with reconstruction as treatment, IBR, especially implant-based IBR,
has become a common procedure to restore the shape of
the breast and improve psychological well-being.33 Breast
surgery is historically thought of as a “clean” procedure,14
and for clean surgical procedures, the CDC calls for the
discontinuation of perioperative prophylactic antibiotics
within 24 hours.12 In recent years, some have advocated
breast surgeries as “clean-contaminated” procedures,34,35
noting the breast microbiome36,37 and bacteria presence on
normal breast implants,38 and of contamination of breast
implants even when precautions are taken.39 However, this
may be more complicated than applying a blanket label
for all breast surgeries, because the SSI rates after different breast surgeries have varied widely in the published
literature, ranging from 0.8% to 26%.40,41 Among all types
of procedures, mastectomy with implant-based IBR has a
2-fold increase in SSI incidence compared with mastectomy
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alone.42 Therefore, antibiotics are usually prescribed for an
extended duration after mastectomy with IBR even though
there is a lack of clinical evidence. Such practice has been
prone to criticism by infection control officers and others
who quote data from studies suggesting no corresponding
decrease in rates of postoperative infection despite increasing use of prophylactic antibiotics.16,43–45 During that time,
a center implemented changes to not provide postoperative prophylactic antibiotics for breast reconstruction
(from previous practice of giving postoperative antibiotics
until drains were removed). They reported that this is associated with an increased risk of infection.18 The group then
proposed an RCT to test out the optimal duration of postoperative antibiotics. Amid the controversy, there is still no
consensus for reconstructive breast surgeries, including
postmastectomy implant-based IBR.
Our study aimed to examine the correlation of extended
antibiotic prophylaxis (>24 hours postoperatively) and
the incidence of SSI after IBR. The average SSI rate of
our study population was 5.99%, ranging from 2.83% to
26.2%. Our meta-analysis found that extended postoperative systemic antibiotics had no significant effect on reducing the incidence of SSI. According to our protocol, we
initially aimed to pool all the studies in a forest plot, but
given the heterogeneity of the studies included, this was
not statistically or clinically appropriate. Further subgroup
analysis demonstrated that extended antibiotic prophylaxis
showed no significant effect on reducing the incidence of
wound complications and hospital readmission.
This is the first meta-analysis focusing on the effects
of using extended prophylactic antibiotics for postmastectomy IBR in both topical and systemic antibiotics groups.
However, there are several limitations in our meta-analysis,
which are mostly related to the studies that were analyzed.
First, there are missing data in some of the studies. Three
out of the 11 studies lacked adequate descriptions of their
antibiotic protocols for the comparison groups and most
studies lacked antibiotic protocols and a defined time of
discontinuation.
The second limitation was the heterogeneity of the
included studies. As we mentioned earlier, we divided I2
into 3 categories—low, moderate, and high, with upper
limits of 25%, 50%, and 75%. The average I2 of our studies
is around 60%. According to a previous review, a quarter
of meta-analyses has I2 values over 50%, and quantification
of heterogeneity is only 1 component of a wider evaluation of variability among different studies.26 Thus, metaanalysts must also consider the clinical applications of the
observed level of inconsistency across different studies. In
particular for our studies, antibiotics were not used uniformly in terms of regimens, timing, dosing, and duration.
There was no indication that there was any standardization of what constituted an SSI in the included articles.
Redness, fever, requirement for intraoperative irrigation,
requirement for removal of the implant or expander, and
a combination of the following could technically constitute SSI.46 Thus, having clarity of what makes an SSI would
be very important for any prospectively designed study.
Disagreement on what constitutes an SSI is a commonly
encountered problem when comparing articles discussing
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infection rates, as it may be field specific. We would like
to engage stakeholders and experts in the area of breast
reconstruction to potentially form a consensus for prospective studies that will improve evidence-based practices.
The third limitation is the type of studies included.
Ten of 11 studies were retrospective studies. Since there
was only 1 RCT conducted within the included studies,
more well-designed RCTs should be conducted to demonstrate the effect of different regimens of prophylactic
antibiotics on the SSI rate of IBR. Appropriate prophylactic antibiotic protocols should be tested. Finally, a better
reporting system of the types of SSI, antibiotic regime/
dosage/duration, and other complications should be used
for future studies.
Future Directions

Given the paucity of prospective studies on this
important topic, well-designed studies are sorely needed.
However, there are many prior considerations that go
into a well-designed prospective study for this particular
question. Although we try not to prescribe particular rules
here, the following questions (among others) are important to consider. Should patients with tissue necrosis be
excluded? Should cases done by surgeons who leave completely different flap thicknesses be grouped together?
Should reconstructions going under the muscle be compared to reconstructions done above the muscle? Should
small areas of necrosis count the same as larger areas?
Should the experience of the plastic surgeon be assessed?
Should drain removal be based on drainage volume or
based on duration, and if so, how much? Should patients
who are discharged from hospital with a drain be grouped
separately? It has been noted that these factors, while
important in predicting SSI, are never available from retrospective chart reviews. Importantly, regarding antibiotic
duration, the timepoints of antibiotics for 24 hours only,
antibiotics until drain removal (which can vary significantly), and antibiotics for a certain duration after drain
removal are essential to study and compare. Even if the
sample size is relatively low, such well-controlled prospective studies will be valued. We rally surgeons in this field to
consider starting prospective studies on this.

CONCLUSIONS

From our systematic review and meta-analysis, we conclude that, at this point, in part due to the lack of large
prospective studies and in part due to the heterogeneity
of interventions, there are insufficient data to suggest that
extended antibiotics reduce the risk of SSI in patients
undergoing mastectomy with IBR. Moreover, broad-spectrum antibiotics may significantly influence the normal
gastrointestinal flora and lead to unfavorable clinical
consequences, such as Clostridium difficile–related pseudomembranous colitis and antibiotic resistance. Therefore,
we appeal for RCTs that test if there is improved efficacy
and safety of extended prophylactic antibiotics on IBR. In
particular, focus should be put on the choice of antibiotic
regimens, the treatment duration, and a standardized
clinical criterion for SSI evaluation.
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